RVV — Revive Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00
- CA$12.56m
- CA$12.00m
- 26
- 39
- 17
- 17
2019 June 30th | 2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -1.34 | -5.38 | -20.1 | -17.8 | -6.32 |
Depreciation | |||||
Non-Cash Items | 0.161 | 3.34 | 11.1 | 1.2 | 1.04 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -0.005 | -0.503 | 0.706 | 3.54 | -0.748 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Payable / Accrued Expenses | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -1.18 | -2.52 | -8.31 | -13.1 | -6.03 |
Capital Expenditures | -0.001 | 0 | -3 | 0 | — |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | -0.75 | 0.142 | 0.281 | 0 | — |
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | -0.751 | 0.142 | -2.72 | 0 | — |
Financing Cash Flow Items | — | -0.295 | -2.45 | 0 | — |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 1.35 | 3.28 | 26.2 | 0.376 | 4.2 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -0.585 | 0.906 | 15.2 | -12.7 | -1.83 |